Chevy Chase Trust Holdings LLC Has $39.39 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Chevy Chase Trust Holdings LLC reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 1.1% in the 1st quarter, HoldingsChannel reports. The fund owned 239,219 shares of the company’s stock after selling 2,644 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in Zoetis were worth $39,387,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Mission Wealth Management LP boosted its position in Zoetis by 2.0% during the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock valued at $479,000 after acquiring an additional 59 shares during the last quarter. HUB Investment Partners LLC lifted its stake in shares of Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after purchasing an additional 62 shares during the period. Coppell Advisory Solutions LLC boosted its position in shares of Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company’s stock valued at $68,000 after purchasing an additional 64 shares in the last quarter. Lindbrook Capital LLC grew its stake in Zoetis by 1.8% during the fourth quarter. Lindbrook Capital LLC now owns 3,650 shares of the company’s stock worth $595,000 after purchasing an additional 65 shares during the period. Finally, Ironwood Investment Management LLC increased its holdings in Zoetis by 0.8% in the fourth quarter. Ironwood Investment Management LLC now owns 8,354 shares of the company’s stock worth $1,361,000 after purchasing an additional 68 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 652 shares of the firm’s stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president now directly owns 15,129 shares of the company’s stock, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Stock Up 0.3%

Shares of NYSE ZTS opened at $157.76 on Wednesday. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The stock has a market capitalization of $70.23 billion, a P/E ratio of 28.32, a P/E/G ratio of 2.61 and a beta of 0.94. The company has a 50-day moving average price of $159.89 and a 200-day moving average price of $163.06.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The company’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.38 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. Zoetis’s payout ratio is 35.91%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ZTS shares. Piper Sandler increased their price target on Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Monday, May 12th. UBS Group cut their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $212.13.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.